SCHEMBL10133593

SCHEMBL10133593

O=C(c1ccc(Nc2ccc(-c3cc[nH]c(=O)c3)n3ccnc23)cc1)N1CCCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK5 Q8IW41 2/20 0.49
TYK2 P29597 4/20 0.41
RIPK1 Q13546 2/20 0.40
JAK2 O60674 2/20 0.40
JAK1 P23458 2/20 0.40
JAK3 P52333 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
GRM5 P41594 6/20 0.38
CCNT1 O60563 2/20 0.38
CDK1 P06493 2/20 0.38
CDK4 P11802 2/20 0.38
CCNA2 P20248 2/20 0.38
CCND1 P24385 2/20 0.38
CCNE1 P24864 2/20 0.38
CDK2 P24941 2/20 0.38
CCND3 P30281 2/20 0.38
CDK9 P50750 2/20 0.38
CDK3 Q00526 2/20 0.38
CDK6 Q00534 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10134526 0.93 L3MBTL3 (0.44) MAPKAPK5MEN1KMT2AIKBKBCHUK
SCHEMBL12618756 0.91 MAPKAPK5 (0.58) MAPKAPK5TYK2RIPK1JAK2JAK1
SCHEMBL12618769 0.91 MAPKAPK5 (0.57) MAPKAPK5RIPK1CCNT1CDK1CDK4
SCHEMBL12618807 0.89 MAPKAPK5 (0.47) MAPKAPK5CCNT1CDK1CDK4CCND1
SCHEMBL12618767 0.89 MAPKAPK5 (0.47) MAPKAPK5CCNT1CDK4CCND1CCND3
SCHEMBL10133598 0.89 MAPKAPK5 (0.47) MAPKAPK5TYK2GRM5ROCK2
SCHEMBL12618766 0.87 NAMPT (0.47) MAPKAPK5MEN1KMT2A
SCHEMBL12618800 0.87 MAPKAPK5 (0.44) MAPKAPK5ROCK2
SCHEMBL12618749 0.86 MAPKAPK5 (0.45) MAPKAPK5CCND1CDK6ROCK2
SCHEMBL12618750 0.86 MAPK14 (0.45) MAPKAPK5MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES COL2A1, MMP1, COL1A1 MAPKAPK5 19/4885TYK2 67/4885RIPK1 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.